Effectiveness and feasibility of selective intra-arterial low dose of cisplatin infusion and concomitant radiotherapy for patients with advanced laryngeal cancer with impaired renal function: A retrospective cohort study
Yuji Imahara MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorCorresponding Author
Takeharu Ono MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Correspondence
Takeharu Ono, Department of Otolaryngology – Head and Neck Surgery, School of Medicine, Kurume University, Asahimachi 67, Kurume 830-0011, Japan.
Email: [email protected]
Search for more papers by this authorNorimitsu Tanaka MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorShun-ichi Chitose MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorFumihiko Sato MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorShuichi Tanoue MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorTakashi Kurita MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorYusaku Miyata MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorKoichiro Muraki MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorEtsuyo Ogo MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorChikayuki Hattori MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorToshi Abe MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorHirohito Umeno MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorYuji Imahara MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorCorresponding Author
Takeharu Ono MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Correspondence
Takeharu Ono, Department of Otolaryngology – Head and Neck Surgery, School of Medicine, Kurume University, Asahimachi 67, Kurume 830-0011, Japan.
Email: [email protected]
Search for more papers by this authorNorimitsu Tanaka MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorShun-ichi Chitose MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorFumihiko Sato MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorShuichi Tanoue MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorTakashi Kurita MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorYusaku Miyata MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorKoichiro Muraki MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorEtsuyo Ogo MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorChikayuki Hattori MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorToshi Abe MD
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorHirohito Umeno MD
Department of Otolaryngology – Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
Search for more papers by this authorAbstract
Background
Chemoradiation therapy with high-dose cisplatin is the standard regimen against advanced squamous cell carcinoma of the larynx (SCC-L). However, patients with renal dysfunction are ineligible for this regimen. We investigated the effectiveness and feasibility of selective intra-arterial low-dose cisplatin infusion and radiotherapy (modified [m]-RADPLAT) for patients with impaired renal function.
Methods
We retrospectively reviewed the data of 77 patients with SCC-L who received m-RADPLAT.
Results
Fourteen and 63 patients had creatinine clearance (CrCl) values of 30 ≤ CrCl < 60 mL/min and ≥60 mL/min, respectively. The m-RADPLAT regimen led to no significant changes in serum creatinine or CrCl values post-treatment. The 5-year local control, overall survival, and laryngectomy-free survival rates of the CrCl < 60 and ≥60 groups were 90.0% and 90.5%, 100% and 81.8%, and 100% and 79.0%, respectively. Grade 3 or higher toxicity rates were not significantly different between the groups.
Conclusions
The m-RADPLAT regimen yielded favorable survival rates and clinical outcomes in patients with impaired renal function.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
REFERENCES
- 1Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098.
- 2Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
- 3Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
- 4Szturz P, Wouters K, Kiyota N, et al. Low-dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer. Front Oncol. 2019; 9:86.
- 5Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. Br J Radiol. 2017; 90:20170442.
- 6Trevisani F, Di Marco F, Quattrini G, et al. Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer. Front Oncol. 2023; 13:1173578.
- 7van der Vorst MJDL, Neefjes ECW, Toffoli EC, et al. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer. 2019; 19:1066.
- 8Faig J, Haughton M, Taylor RC, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2018; 41: 432-440.
- 9Bhat ZY, Cadnapaphornchai P, Ginsburg K, et al. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS One. 2015; 10:e0142225.
- 10Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs. 2006; 17: 207-215.
- 11Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head Neck Oncol. 2009; 1:17.
- 12Lau H, Brar S, Hao D, MacKinnon J, Yee D, Gluck S. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: analysis of survival and toxicity. Head Neck. 2006; 28: 189-196.
- 13Espeli V, Zucca E, Ghielmini M, et al. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol. 2012; 48: 266-271.
- 14Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol. 2004; 22: 4657-4659.
- 15Homma A, Onimaru R, Matsuura K, et al. Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): dose-finding phase. Head Neck. 2018; 40: 475-484.
- 16Kiyota N, Tahara M, Mizusawa J, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol. 2022; 40: 1980-1990.
- 17Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck. 1992; 14: 364-371.
- 18Rasch CR, Hauptmann M, Schornagel J, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer. 2010; 116: 2159-2165.
- 19Nagai N, Hotta K, Yamamura H, Ogata H. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1995; 36: 404-410.
- 20Ono T, Tanaka N, Tanoue S, et al. Organ preservation following radiation therapy and concurrent intra-arterial low dose cisplatin infusion for advanced T2 and T3 laryngeal cancer: long-term clinical results from a pilot study. Laryngosc Investig Otolaryngol. 2020; 5: 55-65.
- 21Ono T, Tanaka N, Chitose SI, et al. Comparative treatment outcome in T3N0 glottic cancer with and without vocal fold fixation receiving radiation therapy and concurrent low-dose intra-arterial cisplatin infusion. Ann Otol Rhinol Laryngol. 2022; 131: 897-904.
- 22Pignon JP, le Maître A, Bourhis J, MACH-NC Collaborative Group. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007; 69: S112-S114.
- 23Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 26: 3582-3589.
- 24Al-Mamgani A, Tans L, van Rooij P, Levendag PC. A single-institutional experience of 15 years of treating T3 laryngeal cancer with primary radiotherapy, with or without chemotherapy. Int J Radiat Oncol Biol Phys. 2012; 83: 1000-1006.
- 25Timmermans AJ, de Gooijer CJ, Hamming-Vrieze O, Hilgers FJ, van den Brekel MW. T3-T4 laryngeal cancer in The Netherlands Cancer Institute; 10-year results of the consistent application of an organ-preserving/−sacrificing protocol. Head Neck. 2015; 37: 1495-1503.
- 26Bhateja P, Ward MC, Hunter GH, et al. Impaired vocal cord mobility in T2N0 glottic carcinoma: suboptimal local control with radiation alone. Head Neck. 2016; 38: 1832-1836.
- 27Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11: 21-28.
- 28Maddalo M, Borghetti P, Tomasini D, et al. Cetuximab and radiation therapy versus cisplatin and radiation therapy for locally advanced head and neck cancer: long-term survival and toxicity outcomes of a randomized phase 2 trial. Int J Radiat Oncol Biol Phys. 2020; 107: 469-477.
- 29Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016; 34: 427-435.
- 30Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998; 9: 13-21.
- 31De Andrés L, Brunet J, López-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol. 1995; 13: 1493-1500.
- 32Nishioka T, Shirato H, Fukuda S, et al. A phase II study of concomitant chemoradiotherapy for laryngeal carcinoma using carboplatin. Oncology. 1999; 56: 36-42.
- 33Lu SM, Iganej S, Abdalla IA, Buchschacher GL. Concurrent radiotherapy and triweekly carboplatin for the definitive treatment of locally advanced laryngeal carcinoma. Am J Clin Oncol. 2018; 41: 595-600.
- 34Hamauchi S, Yokota T, Mizumachi T, et al. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Int J Clin Oncol. 2019; 24: 468-475.
- 35Robbins KT, Kumar P, Wong FS, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000; 22: 687-693.
- 36Homma A, Hayashi R, Kawabata K, et al. Association of impaired renal function and poor prognosis in oropharyngeal squamous cell carcinoma. Head Neck. 2016; 38: 1495-1500.
- 37Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005; 23: 1447-1454.
Citing Literature
